Literature DB >> 6090373

Cefodizime, an aminothiazolylcephalosporin. I. In vitro activity.

M Limbert, N Klesel, K Seeger, G Seibert, I Winkler, E Schrinner.   

Abstract

Cefodizime possesses a broad antibacterial spectrum including staphylococci, streptococci and Enterobacteriaceae. Neisseria gonorrhoeae and Haemophilus influenzae are also highly susceptible to cefodizime. Because of its beta-lactamase stability cefodizime is active against bacterial strains producing especially plasmid-coded enzymes. The MICs of cefodizime are slightly higher than those of cefotaxime, but with most Gram-negative bacteria they are lower than those of cefazolin, cefotiam and piperacillin. The in vitro activity of cefodizime is not dependent on inoculum size, or on the pH and composition of the test medium. Cefodizime did not induce in vitro resistance of Staphylococcus aureus or Escherichia coli. Because of its binding properties to PBPs 1A/B and 3, cefodizime leads to filamentation of Gram-negative rods and, at only slightly higher concentrations, to bacteriolysis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6090373     DOI: 10.7164/antibiotics.37.892

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  8 in total

1.  Cefodizime host-defence enhancement: considerations of dose-response relationships in healthy volunteers.

Authors:  G Gialdroni Grassi; P M Shah
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 2.  In vivo activity of cefodizime.

Authors:  P M Shah; H Knothe
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 3.  In vitro activity of cefodizime.

Authors:  H Knothe; P M Shah
Journal:  Infection       Date:  1992       Impact factor: 3.553

4.  Influence of cefodizime on the reagibility of human leukocytes.

Authors:  M Limbert; H Müllner; P M Shah
Journal:  Infection       Date:  1992       Impact factor: 3.553

5.  Cefodizime penetration into skin suction blister fluid following a single intravenous dose.

Authors:  M Schäfer-Korting; H C Korting; L Maass; N Klesel; H G Grigoleit; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

7.  Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers.

Authors:  H C Korting; M Schäfer-Korting; L Maass; N Klesel; E Mutschler
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

8.  Hemostasis in patients with normal and impaired renal function under treatment with cefodizime.

Authors:  K Andrassy; J Koderisch; D Trenk; E Jähnchen; A Iwand
Journal:  Infection       Date:  1987       Impact factor: 3.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.